The Rs 6,480-crore initial public offering (IPO) of the Hyderabad-based Gland Pharma managed to sail through on the back of institutional investor support, even as individual investors shunned the issue.
The institutional investor portion of the IPO was subscribed 6.4x.
Meanwhile, the high networth individual (HNI) portion was subscribed 51 per cent, and retail investor portion subscribed just 24 per cent.
Of the Rs 6,480 crore, less than a sixth came from these two classes of investors — who had nearly 50 per cent of the issue reserved for them.
Experts said the steep pricing of the IPO made a dent in the HNI and retail demand.
“Usually, HNI and retail investors apply on the last day, with an eye on the grey market premium. In this IPO, when the offer document was filed (in July), the expected price band — based on FY20 numbers — was Rs 1,300-1,350 per share. However, the actual price band came in higher after accounting for its Q1FY21 results, and hence the grey market premium fell,” said Geetanjali Kedia, senior research analyst, SP Tulsian Investment Advisory Services.
“This was the primary reason behind HNIs and retail investors staying away from the IPO. Further, risk-on trade is moving away from defensive sectors like IT, and pharma, as expectations of a Covid vaccine build-up,” she added.
The price band was set at Rs 1,490-1,500 per share. At the top end, the company has a market cap of close to Rs 24,500 crore.
Some said demand could also have been hit by the parentage of Gland Pharma. The company’s promoter is China’s Fosun Group, which had picked up a majority stake for $1.2 billion in 2017. The company’s management had claimed during the roadshows that they run their business independently and the tensions between the two countries do not affect their day-to-day operations.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU